[关键词]
[摘要]
Pemafibrate(Parmodia®)是高效的过氧化物酶体增殖激活受体α(PPARα)激动剂,通过选择性结合PPARα受体调控PPARα的表达,从而增加高密度脂蛋白的含量和降低血浆中的三酰甘油水平。该药由日本兴和集团研制,并在2017年7月3日被批准上市,在日本用于治疗高血脂症。就Pemafibrate的化学性质、作用机制、药动学和临床研究等进行概述,以期为临床用药提供帮助。
[Key word]
[Abstract]
Pemafibrate (Parmodia®) is a novel, highly selective peroxisome proliferator-activated receptor (PPAR)-α agonist. It acts by binding to PPAR-α and regulating the expression of target genes that modulate lipid metabolism, thereby leading the reduced plasma triglyceride levels and the increased high-density lipoprotein cholesterol levels. Oral pemafibrate developed by Kowa Company has been approved in Japan on July 3, 2017 for the treatment of hyperlipidemia. The properties, pharmacokinetics, pharmacodynamics, and clinical trials about pemafibrate in the review are introduced to guide the doctors and the patients.
[中图分类号]
[基金项目]